



Precision BioSciences to Present at Upcoming June Investor Conferences

June 5, 2023

DURHAM, N.C.--(BUSINESS WIRE)--Jun. 5, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based *in vivo* gene editing and *ex vivo* allogeneic CAR T therapies, today announced that members of management will participate in the following investor conferences in June 2023:

Jefferies Global Healthcare Conference 2023

Date: Friday, June 9, 2023

Time: 10:30 am ET

Goldman Sachs 44th Annual Global Healthcare Conference

Date: Thursday, June 15, 2023

Time: 8:40 am PT (11:40 am ET)

A live webcast of each presentation will be accessible on the Company's website www.precisionbiosciences.com, under the Investors & Media section. An archived replay of the webcasts will be available for approximately 30 days following each event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of several *in vivo* gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist and multiple *ex vivo* clinical candidates. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20230605005316/en/>

Investor and Media Contact:

Mei Burris

Director, Investor Relations and Finance

Mei.Burris@precisionbiosciences.com

Source: Precision BioSciences, Inc.